Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Ironwood Pharmaceuticals (IRWD) over the last 14 years, with Q3 2025 value amounting to $22.2 million.

  • Ironwood Pharmaceuticals' Other Non-Current Liabilities fell 4413.52% to $22.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.2 million, marking a year-over-year decrease of 4413.52%. This contributed to the annual value of $17.1 million for FY2024, which is 3980.29% down from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Other Non-Current Liabilities of $22.2 million as of Q3 2025, which was down 4413.52% from $22.5 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' 5-year Other Non-Current Liabilities high stood at $39.8 million for Q3 2024, and its period low was $1.5 million during Q2 2021.
  • Over the past 5 years, Ironwood Pharmaceuticals' median Other Non-Current Liabilities value was $17.1 million (recorded in 2024), while the average stood at $17.1 million.
  • Per our database at Business Quant, Ironwood Pharmaceuticals' Other Non-Current Liabilities soared by 47885.82% in 2022 and then plummeted by 4413.52% in 2025.
  • Quarter analysis of 5 years shows Ironwood Pharmaceuticals' Other Non-Current Liabilities stood at $3.5 million in 2021, then skyrocketed by 178.95% to $9.8 million in 2022, then skyrocketed by 190.96% to $28.4 million in 2023, then tumbled by 39.8% to $17.1 million in 2024, then grew by 29.89% to $22.2 million in 2025.
  • Its last three reported values are $22.2 million in Q3 2025, $22.5 million for Q2 2025, and $17.3 million during Q1 2025.